A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11
years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in
people 12 years and over.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines Development for Global Health Medicines Development Limited